Related Experiment Video
Updated: May 28, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Selective Therapeutic Potential of a H2O2-Inducible DNA Interstrand Cross-linker in Anaplastic Thyroid Carcinoma
Chenghui Lu1,2, Dehao Yu3, Xufu Wang2
1Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, P. R. China.
Abstract:
We aimed to investigate hydrogen peroxide-inducible DNA interstrand cross-link (HP-ICL) as a targeted therapy for anaplastic thyroid cancer (ATC) due to its higher H2O2 content than normal cells. In vitro analysis included fluorescence microscopy for H2O2 levels and exposure of ATC cells to various HP-ICL concentrations followed by assessment of cell viability, apoptosis, cell cycle, and DNA damage using methyl thiazolyl tetrazolium (MTT), flow cytometry, and a γH2AX assay. Protein levels related to apoptosis and the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway were measured by Western blotting. An ATC xenograft mouse model was used to evaluate the HP-ICL's in vivo effects. ATC cells had higher H2O2 levels than normal thyroid cells. HP-ICL treatment caused a dose-dependent decrease in cell viability and an increase in apoptosis, with a slight G2/M phase arrest. A 30 µM HP-ICL treatment doubled γH2AX foci. Bcl-2 levels decreased, while Bax, cleaved-Caspase 3, and PARP increased in a dose-dependent manner. It also inhibited p-PI3K, p-AKT, and p-mTOR. In vivo, the HP-ICL significantly inhibited tumor growth while maintaining body weight and without causing organ damage or altering thyroid hormone levels. Additionally, tumor sections exhibited increased TUNEL staining, decreased Ki67 expression, and reduced levels of p-PI3K, p-AKT, and p-mTOR. The HP-ICL significantly inhibited ATC both in vitro and in vivo, suggesting its potential as an effective therapy for ATC.
Insights
Hydrogen peroxide-inducible DNA interstrand cross-link (HP-ICL) effectively targets anaplastic thyroid cancer (ATC) by exploiting higher H2O2 levels. This novel therapy shows significant in vitro and in vivo efficacy, inhibiting tumor growth and inducing apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Anaplastic thyroid cancer (ATC) exhibits elevated hydrogen peroxide (H2O2) levels compared to normal thyroid cells.
- Targeting cellular H2O2 levels presents a potential therapeutic strategy for ATC.
Purpose of the Study:
- To investigate the efficacy of hydrogen peroxide-inducible DNA interstrand cross-link (HP-ICL) as a targeted therapy for ATC.
- To evaluate the in vitro and in vivo effects of HP-ICL on ATC cell viability, apoptosis, DNA damage, and key signaling pathways.
Main Methods:
- In vitro studies involved assessing H2O2 levels, cell viability (MTT), apoptosis, cell cycle, DNA damage (γH2AX assay), and protein expression (Western blotting) in ATC cells treated with HP-ICL.
- In vivo efficacy was evaluated using an ATC xenograft mouse model, monitoring tumor growth, body weight, and organ damage.
Main Results:
- HP-ICL treatment significantly reduced ATC cell viability, increased apoptosis, and induced G2/M phase arrest.
- HP-ICL elevated DNA damage markers (γH2AX), modulated apoptosis-related proteins (Bcl-2, Bax, cleaved-Caspase 3, PARP), and inhibited the PI3K/AKT/mTOR pathway.
- In vivo, HP-ICL suppressed tumor growth, with reduced proliferation markers (Ki67) and inhibited signaling pathways in tumor tissues, without significant toxicity.
Conclusions:
- HP-ICL demonstrates potent anti-cancer activity against ATC both in vitro and in vivo.
- The findings suggest HP-ICL is a promising targeted therapeutic agent for anaplastic thyroid cancer.

